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Abstract
Introduction: Antiphospholipid syndrome is an autoimmune disorder characterized by either a
history of vascular thrombosis (one or more clinical episodes of arterial, venous, or small vessel
thrombosis in any tissue or organ) or pregnancy morbidity in association with the presence of
antiphospholipid antibodies. The systemic features of the syndrome are characterized by large
variability depending on the affected organ(s). Among them, neurological and behavioural
disturbances, dermatological features as livedo reticularis and renal, ocular, liver or valvular heart
manifestations have been reported in antiphospholipid syndrome patients. However, studies on the
frequency and clinical presentation of the ocular manifestations as the prevailing (first) sign of
antiphospholipid syndrome in patients suffering from "unexplained" ocular disease are missing.
Herein, we present three cases suffering from unexplained ocular disease as first manifestation of
antiphospholipid syndrome.
Case presentation: All the three patients were referred to our department because of
unexplained ocular features from the anterior or posterior segment and unexplained neuro-
ophthalmologic symptoms. The first patient had bilateral retinal occlusive disease, the second and
the third patient had unilateral nonarteritic anterior ischemic optic neuropathy with macular
oedema. Moderate to high levels of antiphospholipid antibodies were detected in all of them at
baseline as well as 6 to 12 weeks after initial testing confirming the presence of antiphospholipid
antibodies. Anticoagulant treatment with acenocoumarol was instituted resulting in stabilization
and/or improvement of ocular signs in all of them.
Conclusion: Due to the important diagnostic and therapeutic implications of antiphospholipid
syndrome, the possibility of ocular features as the first clinical manifestation of antiphospholipid
syndrome should be kept in mind of the physicians particularly in patients with no evident risk
factors for ocular disease. In this case, prompt anticoagulant treatment and close follow-up seem
to be essential for vision salvation and stabilization.
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The antiphospholipid syndrome (APS) is an autoimmune
disorder characterized by either a history of vascular
thrombosis (one or more clinical episodes of arterial,
venous, or small vessel thrombosis in any tissue or organ)
or pregnancy morbidity in association with the presence
of antiphospholipid (aPL) antibodies [1-3]. These anti-
bodies namely, anticardiolipin (aCl) antibodies, lupus
anticoagulant (LA), or antibodies against beta2-glycopro-
tein I (anti-b2GPI) either of IgG or IgM isotype have been
recently established as the laboratory criteria for the diag-
nosis of definite APS [1].
The systemic features of the syndrome are characterized
by large variability depending on the affected organ(s). In
this context, neurological and behavioral disturbances,
dermatological features as livedo reticularis and renal,
ocular, liver or valvular heart manifestations have been
reported in APS patients [1,3,4].
Ocular involvement in APS includes a broad spectrum of
manifestations from the anterior and posterior segment or
the presence of neuro-ophthalmologic features [4-9]. In
brief, conjuctival telangiectasia or conjuctival microaneu-
rysms, episcleritis, limbal or filamentary keratitis and iritis
have been described as the APS ocular features from the
anterior segment [8,9], vitritis, retinal detachment, poste-
rior scleritis, branch or central retinal vein occlusion,
bilateral choroidal infarction, cilioretinal artery occlusion,
venous tortuosity, retinal hemorrhages, cotton-wool spots
and central serous type chorioretinopathy from the poste-
rior segment [4,8] and monocular or bilateral transient
visual loss, transient visual field loss, ischemic optic neu-
ropathy and progressive optic nerve atrophy as the neuro-
ophthalmologic features of APS [4,5].
However, studies on the frequency and clinical presenta-
tion of the ocular manifestations as the prevailing (first)
sign of APS in patients suffering from "unexplained" ocu-
lar disease are missing. Recently, we have reported a
patient with "unexplained" bilateral choroidal emboliza-
tion as the first clinical manifestation of the underlying
APS [10]. Herein, we report 3 additional cases suffering
from "unexplained" ocular disease as first manifestation
of APS in a well-defined geographical region of Greece
[11,12] and describe the clinical manifestations, diagnosis
and course, imaging findings, management and the final
outcome of patients as similar data is missing.
Case presentations
In all 3 cases the ocular features considered "unexplained"
after an extensive investigation which included the fol-
lowing: absence of systemic arterial hypertension, diabe-
tes mellitus and/or impaired glucose tolerance,
hyperlipidemia, heart disease including embolizating car-
diomyopathy, carotid atherosclerosis, multiple sclerosis
and obvious infections. Therefore, the patients were
referred to the department of medicine for thorough
investigation. Special attention was paid to the presence
of past or present history of arterial hypertension (systolic
blood pressure greater than 135 mmHg and diastolic
blood pressure greater than 85 mmHg on several occa-
sions or taking antihypertensive drugs), diabetes mellitus
(considered present if fasting serum glucose levels were
equal or above 126 mg/dl in more than one occasion or
random serum glucose levels equal or above 200 mg/dl in
more than one occasion), impaired glucose tolerance
(considered present if repeatedly fasting serum glucose
levels were between 110 and 125 mg/dl or serum glucose
levels after 2 hours of 75 gr glucose ingestion in between
126 and 199 mg/dl), hyperlipidemia defined as fasting
serum triglycerides equal or greater than 200 mg/dl or
fasting serum cholesterol between 200 and 240 mg/dl
accompanied by increased LDL cholesterol levels (above
160 mg/dl) or cholesterol levels greater than 240 mg/dl
irrespective of LDL cholesterol levels [13]. Heart disease
was investigated for the presence of clinical, electrocardi-
ographic and echocardiographic signs of valvular disease,
myocardial infarction, atrial fibrillation, ventricular
arrhythmias, conduction defect blocks, and left atrial
enlargement. Significant atherosclerosis was considered
when carotid echo-Doppler investigation revealed flow
reduction greater than 60%. Absence of multiple sclerosis
was defined if there was no clinical evidence of the disease
and magnetic resonance imaging of brain and spinal cord
were normal. The absence of infections was defined by
thorough clinical investigation, repeatedly negative blood
and urine cultures and seronegativity by specific enzyme
linked immunosorbent assays (ELISAs) and molecular
techniques for several bacteria and viral antigens includ-
ing human immunodeficiency virus (HIV), herpes sim-
plex virus (HSV), hepatitis B virus (HBV) and hepatitis C
virus (HCV) [14,15].
Case report 1
A 39-years-old Greek male patient of Caucasian origin
referred to our department due to floaters perception
bilaterally since 3 weeks. His past history was unremarka-
ble. His visual acuity was 20/20 bilaterally. Anterior
chamber of the right eye (RE) presented with a mild flare
while anterior chamber of the left eye (LE) appeared nor-
mal. Fundus examination revealed moderate vitritis in
both eyes and extensive arterial occlusive vasculitis and
retinal haemorrhages in the mid-periphery (Figure 1),
findings that were confirmed by fluorescein angiography
(Figure 2).
Physical examination, and routine haematological and
biochemical laboratory work-up including erythrocyte
sedimentation rate were unrevealing. Repeated blood cul-Page 2 of 6
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while serology tests for several bacteria, viruses and toxo-
plasma tested negative. Aqueous humor, taken by RE
paracentesis, tested also negative by polymerase chain
reaction for HSV1/2, CMV, V-ZV, EBV, mycobacterium
tuberculosis and bacteria infections. Abdominal ultra-
sonography, computed tomographies scan of the lungs,
the upper and lower abdomen as well as the retro-perito-
neal space, magnetic resonance imaging of the brain and
carotid Doppler-testing revealed no findings revealed no
findings. Concentrations of C3 and C4 components of the
complement, angiotensin converting enzyme, immu-
noglobulins, rheumatoid factors and C-reactive protein
and 24 hours urine calcium concentrations were within
normal limits, while antinuclear (ANA), smooth muscle
(SMA), anti-mitochondrial (AMA), anti-dsDNA and anti-
neutrophil cytoplasmic antibodies (ANCA)were undetec-
table.
Further testing gave a high positive result (231 BI; cut-off:
100 BI) for IgG-aCL antibodies by using a highly sensitive,
specific and internationally accepted quantitative solid
phase ELISA as we described previously [2,10,16-18],
while LA ratio determined using the diluted Russell's viper
venom test according to the manufacturer's instructions
(HemosIL™, Instrumentation Laboratory Company-Lex-
ington, USA) was 1.6 (moderate titre; normal values <
1.2) [10]. IgG and IgM anti-b2GPI antibodies were deter-
mined by a commercial ELISA according to the manufac-
turer's instructions (QUANTA Lite™ β2-GPI IgG and IgM,
INOVA Diagnostics; cut-off: 20 SU) and were negative.
His prior history of arteriovenous thrombotic events
(myocardial infraction, ischemic stroke, pulmonary
emboli, deep venous thrombosis of legs, arms or internal
organs) or neuropsychiatric disorders (convulsions,
migraine, memory loss, chorea or psychosis) was not con-
tributory for previous APS symptoms. Thorough investi-
gation for clinical and laboratory criteria of autoimmune
rheumatic diseases as systemic lupus erythematosus,
Sjogren's syndrome, rheumatoid arthritis, systemic angii-
tis, sarcoidosis and seronegative arthritis including Beh-
cet's syndrome and adult Still's disease was unrevealing.
The patient started promptly anticoagulant treatment
with acenocoumarol with a target INR of 2.5-3.0. The IgG-
aCL titre remained high positive 6-12 weeks after the first
test (258 BI), whereas LA test showed again moderate titre
(1.65) confirming the presence of APS. At a 5-month fol-
low-up the patient underwent pan-retinal laser photoco-
agulation since bilateral retinal neovascularization was
found. At the 20th month of follow-up he is still in anti-
coagulant therapy with very good treatment-efficacy
regarding the INR values and without side effects; his vis-
ual acuity remains 20/20, without vitritis and no sites of
neovascularization in fluoroscein angiography.
Case report 2
A 32-years-old Greek female of Caucasian origin was
admitted due to RE floaters perception and visual
obscuration. Her past medical history was not contribu-
tory. She was not smoker or alcohol consumer. Her visual
acuity was 20/25 in the RE and 20/20 in the LE. The ante-
rior segment and intraocular pressure tested normal. Fun-
dus examination revealed a partial nasal edema of the RE
optic disc confirmed by fluoroscein angiography (Figure
RE fundus photography shows vascular occlusion and vitritis (Case 1)Figure 1
RE fundus photography shows vascular occlusion and 
vitritis (Case 1).
RE fluorescein angiography shows peripheral ischemic vascu-litis (Cas  1)Figure 2
RE fluorescein angiography shows peripheral 
ischemic vasculitis (Case 1).Page 3 of 6
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fundus examination. Visual fields (30-2, Humphrey)
revealed normal responses in the LE and an inferior sec-
tional temporal scotoma in the RE. Based on the above
findings the diagnosis of a mild nonarteritic anterior
ischemic optic neuropathy (NAION) was made.
Physical examination and all thorough investigation as it
was reported in case 1 were unrevealing. Further testing
however, gave a high positive result for IgG-aCL antibod-
ies, (207 BI), while LA tested negative and IgG anti-b2GPI
antibodies positive (35 SU). The questionnaire for signs
or symptoms suspicious of prior APS history was negative.
The patient started anticoagulant treatment with aceno-
coumarol. The IgG-aCL titres remained high positive (230
BI and 277 BI) 6 and 12 weeks after first testing. At the 2-
month follow-up the RE optic disc oedema resolved leav-
ing nasal partial optic disc atrophy and the visual field
revealed partial improvement of the defect. The patient
was evaluated at 6-month intervals and in the last follow-
up -2 years later- her visual acuity remains stable. She is
still under anticoagulant treatment with excellent treat-
ment-efficacy regarding the INR values and without side
effects.
Case report 3
A 62-years-old Greek male patient of Caucasian origin was
referred to our department for LE reduced vision due to
NAION, diagnosed by his private ophthalmologist. His
best-corrected visual acuity was 20/20 (RE) and 20/400
(LE). Visual fields revealed normal responses in RE and a
lower altitudinal defect in LE. Fluorescein angiography
showed a lower segmental hyperfluorescence of the LE
optic disk in the late phases. He was not smoker or alco-
hol consumer. As in the previous two cases, physical
examination and all investigations were unrevealing. Fur-
ther testing however, gave a moderate positive moderate
result for IgG-aCL antibodies (178 BI), which became
strong positive at 6 weeks determination after the first test
(216 BI). LA and anti-b2GPI antibodies tested negative.
The patient started anticoagulant treatment with aceno-
coumarol. Follow-up at 1-month intervals showed a slow
progressive improvement of the LE visual acuity reached
the 20/64 level within 5 months period, which is so far
the last follow-up of the patient. His LE optic disk was
found pale.
Discussion
These cases demonstrate that the ocular features as the
first presenting sign of APS though rare, should alert the
clinicians for APS possibility, particularly when conven-
tional risk factors have been excluded and the onset of
ocular symptoms are insidious [5,7,8,19]. Although the
involvement of anterior segment is not rare, the manifes-
tations from the posterior segment such as vasculitis, vit-
ritis, retinal detachment, posterior scleritis and central
retinal artery occlusion appear to be more prominent
among APS patients [4,8]. Of these, the most common
and the most serious is vasculitis, which can result in vaso-
occlusive disseminated retinopathy as in our first case. Of
note, APS-related retinal artery occlusions are character-
ized by a strong tendency to retinal neovascularization, as
in our first case [9]. In these cases, pigment epithelial win-
dow defect has been reported as the most frequent finding
in fluorescein angiography. Neuro-ophthalmological
manifestations related to APS are also common as monoc-
ular or bilateral transient visual loss, transient visual field
loss or anterior ischemic optic neuropathy [4,6,8]. In our
case series, 2 out of 3 patients presented with NAION, one
female young adult (case 2) and one healthy middle aged
male (case 3).
Previous studies on aPL prevalence in ocular vascular
events are scarce, mostly retrospective having been per-
formed in old patients with concurrent risk factors. In a
recent study, Cobo-Soriano et al [7] found aCL positivity
in 9/40 (22.5%) patients with retinal thrombosis without
main conventional risk factor for thrombosis though, aCL
titres were that of low positive in most instances and APS
was confirmed finally in 3/9 aCL positive patients [7]. Fur-
thermore, in the latter study no detailed data is given in
order to assess whether these manifestations were the first
features of APS [7]. In another recent pilot study, Marcucci
RE fluorescein angiography in Case 2 shows optic disk seg-mental hyp rfluorescence (arrow) in late phases (arrow)Figure 3
RE fluorescein angiography in Case 2 shows optic disk 
segmental hyperfluorescence (arrow) in late phases 
(arrow).Page 4 of 6
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for aCL in a group of 41 unselected patients with retinal
artery occlusion. However, aPL prevalence in that study
was probably overestimated as it was based on a single
determination, while the statistically significant associa-
tion of these antibodies with the presence of retinal artery
occlusion was not maintained after multivariate analysis
[19]. From the few studies reported in the literature, only
hyperhomocysteinemia among thrombophilic factors,
seems to be an independent risk factor for retinal artery
occlusion [19,20], whereas data available on other throm-
bophilic factors including aPL antibodies are still incon-
clusive. However, the aim of our study was different from
the abovementioned studies as we tried for the first time
to report cases suffering from "unexplained" ocular dis-
ease as the first manifestation of APS.
From the clinical point of view we believe that the detec-
tion of aPL antibodies could be of interest and relevance
in medicine as it can provide -at least in part- a new over-
view of the pathogenesis of some ocular diseases particu-
larly in young patients without known evident risk
factors. In addition, although the last revised criteria for
the classification of APS [1] do not include several well-
known features which are associated with APS, we believe
that the repetitive detection of aPL antibodies (6 and/or
12 weeks from first testing) has important diagnostic and
therapeutic implications as seems to confirm APS diagno-
sis and subsequently indicates the need of anticoagulation
therapy, which can prevent not only future events in the
eyes but also episodes in other vital organs [1,2,4,5,10].
APS prognosis clearly depends on the severity of the dis-
ease, the thrombotic events, recurrences and the side
effects of treatment [3]. However, the prognosis of ocular
diseases due to APS is not well documented, as long-last-
ing prospective studies are missing. Though there is still
no definite agreement for the duration of anticoagulant
treatment, it seems rational and prudent to treat these
patients lifelong targeting an INR between 2.5 and 3.0,
while the role, if any, of corticosteroids is unclear.
Conclusion
As APS diagnosis has important diagnostic and therapeu-
tic implications, we do believe that the possibility of APS
should be considered by the internists in cases with
"unexplained" ocular manifestations who have no evi-
dent risk factors since prompt administration of anticoag-
ulant treatment is known to be essential for APS outcome
and potentially for vision salvation and stabilization.
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